Tranexamic acid - Leading BioSciences

Drug Profile

Tranexamic acid - Leading BioSciences

Alternative Names: InflammaGen Shok-Pak; LB-1148

Latest Information Update: 28 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Leading BioSciences
  • Developer Leading BioSciences; VA San Diego Healthcare System
  • Class Antifibrinolytics; Antihaemorrhagics; Cyclohexanecarboxylic acids; Skin disorder therapies; Small molecules
  • Mechanism of Action Serine protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Cardiogenic shock; Post-surgical adhesions; Postoperative ileus; Septic shock
  • Phase I Haemorrhagic shock

Most Recent Events

  • 27 Mar 2017 Phase-I clinical trials in Haemorrhagic shock in USA (Enteral) (Leading Biosciences Pipeline, March 2017)
  • 27 Mar 2017 Phase-II development for Cardiovascular surgery complications is ongoing in Taiwan
  • 27 Mar 2017 Phase-II development for Septic shock is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top